Evidence map›Paper›PMID 32269465›Full record

SynthesisEthnicity & disease2020

Exploring Biologic Predictors Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review.

Rebecca N Jerome, Jill M Pulley, Nila A Sathe, Shanthi Krishnaswami, Alyssa B Dickerson, Katherine J Worley, Consuelo H Wilkins

Open access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in Ethnicity & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Uncovering Outcome Disparities of βJournal of the National Medical Association · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rebecca N JeromeVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN.
Jill M PulleyVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN.
Nila A SatheVanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN.
Shanthi KrishnaswamiVanderbilt Evidence-Based Practice Center, Institute for Medicine and Public Health, Vanderbilt University Medical Center, Nashville, TN.
Alyssa B DickersonVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN.
Katherine J WorleyVanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, TN.
Consuelo H WilkinsDepartment of Medicine, Vanderbilt University Medical Center and Department of Internal Medicine, Meharry Medical College, Nashville, TN.
Vanderbilt University Medical Center · USMeharry Medical College · USVanderbilt Health · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Training and Mentoring CoreU54MD010722 · NIMHD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COX, NANCY J · 2016 to 2020
$11.9M
NCATS NIH HHS UL1 TR002243NIMHD NIH HHS U54 MD010722
6 · The paper itself

Abstract

Purpose: Management of schizophrenia among Blacks in the United States is affected by persistent disparities. This review explored response to atypical antipsychotics among Blacks compared with other groups to assess systematic variation that may contribute to disparities. Methods: We conducted a quasi-systematic review of studies reporting response to atypical antipsychotics among Blacks compared with other groups, including effects of genetic variation. Results: Of 48 identified research articles, 29 assessed differences in outcomes without inclusion of genetic variation and 20 explored effects of genetic variation; of note: one article included both types of data. Analysis of the 29 papers with clinical outcomes only suggests that while data on efficacy and risk of movement disorders were heterogeneous, findings indicate increased risk of metabolic effects and neutropenia among Blacks. Of the 20 articles exploring effects of genetic variation, allelic or genotypic variations involving several genes were associated with altered efficacy or safety among Blacks but not Whites, including risk of decreased response involving variation in Conclusions: The current analysis can help tailor management among Blacks using an atypical antipsychotic. Heterogeneity in genetic variation effects and response allele frequency suggests that pharmacogenetics approaches for atypical antipsychotics will need to explicitly incorporate race and ethnicity.

Indexed as

Health Status DisparitiesAntipsychotic AgentsBlack or African AmericanHumansOutcome Assessment, Health CareSchizophreniaSchizophrenic PsychologyTreatment OutcomeUnited StatesAntipsychotic AgentsAtypical AntipsychoticsBlacksDisparitiesPharmacogeneticsSchizophrenia

Identifiers

PMID32269465
PMCPMC7138445
OpenAlexW3014750914

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.